WeVote
Log In

Bill

Bill

SB 527

Pharmaceutical Substance Manufacturing Grant Fund; created.

2026 Regular Session Introduced by Creigh Deeds

Virginia establishes a grant fund to support pharmaceutical manufacturing operations, aiming to attract industry investment and create high-wage jobs within the state.

Approved by Governor-Chapter 809 (effective 7/1/2026)
0
WeVote Research Nonpartisan
Bill Summary · SB 527

Legislative bill overview

SB 527 establishes a new grant fund in Virginia to support pharmaceutical substance manufacturing operations and infrastructure development. The bill creates a financial mechanism to incentivize and support pharmaceutical manufacturing businesses within the state through grants distributed by state agencies.

Why is this important

Pharmaceutical manufacturing represents a high-value economic sector that generates well-paying jobs and strengthens state tax revenue. Virginia's ability to attract or expand pharmaceutical manufacturing could reduce regional dependence on other industries and position the state as a competitive hub for this essential sector.

Potential points of contention

  • Funding source clarity: The bill's fiscal impact statement should specify whether funds come from general revenue, bonds, or other sources, and whether existing programs are being redirected
  • Grant criteria and accountability: Questions about how grants will be awarded, what performance metrics companies must meet, and mechanisms to ensure public funds generate promised economic benefits
  • Competitive advantage concerns: Debate over whether state subsidies create unfair advantages or are necessary to compete with other states' pharmaceutical incentive programs

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.